Cargando…
A Comment on Boyers et al.: “Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal”
Autores principales: | Allen, Rachel, Brainsky, Andres, Grotzinger, Kelly, Roccia, Tito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing AG
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693436/ https://www.ncbi.nlm.nih.gov/pubmed/23329595 http://dx.doi.org/10.1007/s40273-012-0003-8 |
Ejemplares similares
-
Borderline Thrombocytopenia or Mild Idiopathic Thrombocytopenic Purpura?
por: Zimmer, Jacques, et al.
Publicado: (2006) -
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Rice, Lawrence
Publicado: (2009) -
Idiopathic Thrombocytopenic Purpura Masquerading Paediatric SLE
por: Barara, Meenu, et al.
Publicado: (2015) -
Steroid-Refractory Chronic Idiopathic Thrombocytopenic Purpura Responding to Combination Therapy With Eltrombopag and Rituximab
por: Ahmed, Mohanad, et al.
Publicado: (2020) -
Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine
por: Julian, Jeffrey A., et al.
Publicado: (2021)